Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sohn, Sang Kyun | - |
dc.contributor.author | Oh, Suk Joong | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Ryoo, Hun Mo | - |
dc.contributor.author | Chung, Joo Seop | - |
dc.contributor.author | Joo, Young Don | - |
dc.contributor.author | Bang, Soo Mee | - |
dc.contributor.author | Jung, Chul Won | - |
dc.contributor.author | Kim, Dong Hwan | - |
dc.contributor.author | Yoon, Sung Soo | - |
dc.contributor.author | Kim, In Ho | - |
dc.contributor.author | Lee, Hong Ghi | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Min, Yoo Hong | - |
dc.contributor.author | Cheong, June Won | - |
dc.contributor.author | Park, Joon Seong | - |
dc.contributor.author | Eom, Ki Seong | - |
dc.contributor.author | Hyun, Myung Soo | - |
dc.contributor.author | Kim, Min Kyoung | - |
dc.contributor.author | Kim, Hawk | - |
dc.contributor.author | Park, Moo Rim | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Kim, Chul Soo | - |
dc.contributor.author | Kim, Hyeoung Joon | - |
dc.contributor.author | Kim, Yeo Kyeoung | - |
dc.contributor.author | Park, Eun Kyung | - |
dc.contributor.author | Zang, Dae Young | - |
dc.contributor.author | Jo, Deog Yeon | - |
dc.contributor.author | Moon, Joon Ho | - |
dc.contributor.author | Park, Seon Yang | - |
dc.date.accessioned | 2021-09-07T12:08:19Z | - |
dc.date.available | 2021-09-07T12:08:19Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2011-06 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/112372 | - |
dc.description.abstract | To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 +/- 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with < 1000: 80.6% vs. 19.4%; >= 1000: 94.6% vs. 5.4%; p=0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with < 1000: 3.2% vs. 96.8%; >= 1000: 21.4% vs. 78.6%; p=0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of >= 1000 compared with those with a level of < 1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (< 1000 ng/mL). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | INFORMA HEALTHCARE | - |
dc.subject | CHRONIC MYELOGENOUS LEUKEMIA | - |
dc.subject | MOLECULAR RESPONSES | - |
dc.subject | CHRONIC-PHASE | - |
dc.subject | RESISTANCE | - |
dc.subject | THERAPY | - |
dc.subject | MESYLATE | - |
dc.subject | CML | - |
dc.subject | PHARMACOKINETICS | - |
dc.subject | OVEREXPRESSION | - |
dc.subject | STI571 | - |
dc.title | Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Byung Soo | - |
dc.identifier.doi | 10.3109/10428194.2011.563885 | - |
dc.identifier.scopusid | 2-s2.0-79957452443 | - |
dc.identifier.wosid | 000290869100017 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, v.52, no.6, pp.1024 - 1029 | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.citation.title | LEUKEMIA & LYMPHOMA | - |
dc.citation.volume | 52 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1024 | - |
dc.citation.endPage | 1029 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | CHRONIC MYELOGENOUS LEUKEMIA | - |
dc.subject.keywordPlus | MOLECULAR RESPONSES | - |
dc.subject.keywordPlus | CHRONIC-PHASE | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MESYLATE | - |
dc.subject.keywordPlus | CML | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | OVEREXPRESSION | - |
dc.subject.keywordPlus | STI571 | - |
dc.subject.keywordAuthor | Chronic myeloid leukemia | - |
dc.subject.keywordAuthor | imatinib | - |
dc.subject.keywordAuthor | trough blood level | - |
dc.subject.keywordAuthor | cytogenetic response | - |
dc.subject.keywordAuthor | molecular response | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.